Developer docs
API playgroundTry for free, no card

Search company profiles

Mirvie

Full company profile

uuid0000fy7

Namestring
Mirvie
Legal namestring
Mirvie, Inc.
Websiteurl
mirvie.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mirvie is a molecular diagnostics company that develops non-invasive blood tests designed to predict pregnancy complications months before clinical symptoms appear. Its proprietary Mirvie RNA Platform analyzes tens of thousands of cell-free RNA messages originating from the mother, baby, and placenta, combined with machine learning, to identify pregnancies at risk for preeclampsia, preterm birth, severe fetal growth restriction, and other complications. The company was founded in 2018 in South San Francisco, California, where it operates a CLIA-certified laboratory performing high-complexity clinical testing under a Breakthrough Device designation from the FDA granted in May 2022.

The company's first commercial product, the Encompass Preeclampsia Test, launched in May 2025 and is positioned as a direct-to-consumer kit taken between 18 and 22 weeks of gestation. Customers order through mirvie.com or encompassstest.com, receive a mailed kit, schedule an at-home blood draw through Getlabs mobile phlebotomists, and view results through the 1health.io platform. Encompass is bundled with a personalized preventive action plan and a responsive virtual assistant for ongoing support. Mirvie is also piloting the test with healthcare provider networks (Advantia Health) and employer benefits platforms (WIN / WINMaternity) to embed predictive screening into clinical and benefits workflows beyond DTC.

Mirvie has raised approximately $90 million in equity financing across seed and Series B rounds (notably a $60 million Series B led by Decheng Capital in May 2022), supplemented by a $15 million debt facility from Comerica Bank, a $4.6 million Bill & Melinda Gates Foundation grant for Sub-Saharan Africa research, and an additional 2025 financing reported by third-party data. Revenue is generated primarily through one-time per-test fees to consumers; the company does not publicly disclose pricing and has stated it makes no representation regarding insurance reimbursement.

Short descriptiontext

Mirvie is a molecular diagnostics company that uses its proprietary cell-free RNA platform and machine learning to predict pregnancy complications such as preeclampsia and preterm birth months before symptoms, selling its Encompass test direct-to-consumer and through healthcare and employer-benefit pilots.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prenatal diagnostic testing, maternal-fetal health, cell-free RNA analysis, preeclampsia prediction, non-invasive pregnancy testing
Industry4 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLALAHAK
Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
NAICS code3 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Prenatal Diagnostic Testing
Social media profiles4 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Direct-to-Consumer Diagnostic Test Sales
TypeOne Time License
Description

Mirvie sells Encompass test kits directly to pregnant consumers through its e-commerce storefronts (mirvie.com and encompassstest.com). Customers pay for the test upfront, with installment payment options available. Results are delivered through a third-party platform (1health.io).

mirvie.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Encompass Preeclampsia Test — at-home blood test with results and preventive action plan
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Pricing not publicly listed on the website. Users must purchase the test through the checkout process. The company explicitly states it makes no representation or warranty that the test will be eligible for insurance reimbursement.

mirvie.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 record
1Encompass
Description

First-of-its-kind personalized risk prediction test for preeclampsia using a simple blood test, combined with a preventive action plan and responsive virtual assistant for individualized support during pregnancy.

mirvie.com
Core offering1 text field

Mirvie develops and sells the Encompass Preeclampsia Test, a non-invasive at-home blood test taken between 18-22 weeks of gestation that predicts personalized preeclampsia risk months before symptoms appear. The test is powered by the proprietary Mirvie RNA Platform, which analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. The company also pursues enterprise healthcare partnerships with health systems and benefits providers to embed the test in clinical workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Mirvie RNA platform identifies 75% of women who go on to develop preeclampsia, months before symptoms appear. Only 20% of pregnancy complications can be predicted using current generalized risk assessments.
+4 more records
Product overview1 text field

Mirvie offers a platform-plus-modules product architecture anchored by the Mirvie RNA Platform. The core platform combines analysis of tens of thousands of RNA messages from the baby, placenta, and mother with machine learning to predict pregnancy complications before symptoms occur. The first commercial product built on this platform is Encompass, which combines a novel blood test for personalized preeclampsia risk prediction with two supporting modules: a Preventive Action Plan and a responsive Virtual Assistant. Together, these provide pregnant women and their care teams with risk assessment, actionable guidance, and ongoing support for the healthiest pregnancy possible.

Product and service1 record
1Encompass Preeclampsia Test
CategoryPrenatal diagnostic test
Description

A first-of-its-kind at-home blood test that predicts personalized preeclampsia risk months before symptoms appear, taken between 18-22 weeks of gestation. Combined with a preventive action plan and a responsive virtual assistant for individualized support throughout pregnancy. Powered by the proprietary Mirvie RNA Platform, it analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. Demonstrated 75% detection rate for preeclampsia overall and 91% identification of preterm preeclampsia in women aged 35+. For pregnant women seeking proactive, personalized pregnancy care and clinicians seeking biology-driven risk stratification.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1WIN (WINMaternity)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

WIN (WINMaternity) partnered with Mirvie to expand its maternal health program, integrating Mirvie's Encompass test for early preeclampsia prediction and prevention. The expanded program includes 24/7 Nurse Advocacy, virtual specialists, biological data-driven screening, and engagement rewards.

mirvie.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-22
Description

Mirvie and Advantia Health launched a first-of-its-kind pilot program in the U.S. using the Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia in asymptomatic pregnant women, enabling clinicians to initiate preventive care.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-26
Description

Mirvie's South San Francisco-based laboratory received CLIA (Clinical Laboratory Improvement Amendments) certification from CMS to perform high-complexity clinical testing, enabling the company to offer its diagnostic tests clinically.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-26
Description

Getlabs provides mobile phlebotomist services for at-home blood draws for Mirvie's Encompass test. Customers schedule a blood draw through Getlabs, whose phlebotomist visits at the scheduled time and location. Use of Getlabs is subject to Getlabs Terms of Service.

51health.io, Inc.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-26
Description

1health.io delivers Mirvie test results to users through its platform. Users create a 1health account to view their Encompass results. 1health also facilitates the account registration process including a health questionnaire. Use of 1health platform is subject to 1health Terms of Use.

mirvie.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-04-27
Description

Mirvie's proprietary RNA technology was invented at Stanford University through Stephen Quake's groundbreaking work on pregnancy-related cell-free RNA. Quake co-founded Mirvie and serves as Scientific Advisory Board Chair. The technology originated from Stanford research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Celula is an emerging diagnostics company developing cfRNA-based tests for pregnancy complications including preterm birth. It overlaps directly with Mirvie's RNA platform approach and represents a potential emerging competitor or future peer.

TypeBroad incumbent
Description

Natera is a major reproductive health diagnostics incumbent with the Panorama NIPT, Empower carrier screen, and Vistara single-gene NIPT, plus enterprise sales infrastructure into OB-GYN offices. It is the most established competitor in the channel Mirvie is pursuing and a natural bundler for cfRNA-based predictive tests.

3Sema4 (now GeneDx)
TypeBroad incumbent
Description

Sema4's reproductive health offering, now part of GeneDx, includes maternal screening and genetic testing. As a broader women's health and rare disease incumbent, it competes for the same hospital and health system relationships Mirvie is targeting with its enterprise pilots.

TypeBroad incumbent
Description

LabCorp is a broad diagnostics incumbent offering the MaterniT21 NIPT and a broad prenatal screening menu. It competes with Mirvie on OB-GYN access, payer contracts, and lab throughput, and is positioned to add cfRNA-based predictive tests to its existing menu.

TypeBroad incumbent
Description

Myriad's Women's Health segment (Foresight, Prequel, SneakPeek) makes it a broad incumbent in carrier screening and NIPT. It has deep payer contracts and OB-GYN relationships that Mirvie must compete with for provider adoption of new predictive tests.

TypeBroad incumbent
Description

Invitae (now part of Labcorp) offers reproductive health genetic testing including carrier screening and NIPT. As a broad incumbent, it competes with Mirvie for the same clinical relationships and payer contracts across prenatal and women's health.

TypeDirect peer
Description

Sera Prognostics is a direct peer in pregnancy complication diagnostics, with the PreTRM test for spontaneous preterm birth risk prediction. They target the same OB-GYN and maternal-fetal medicine customer base with blood-based biomarker testing, competing head-to-head with Mirvie's preterm birth prediction offering.

TypeDirect peer
Description

BillionToOne is a high-growth prenatal diagnostics peer offering UNITY Fetal Antigen and other NIPT products that screen for pregnancy complications. It serves the same pregnant-consumer and OB-GYN segments, and is a credible DTC and enterprise competitor in advanced prenatal screening.

TypeEmerging player
Description

Progenity is an emerging/specialized player in reproductive and maternal health diagnostics with products in prenatal testing and maternal health. It targets a similar OB-GYN channel with a narrower portfolio, making it a relevant emerging competitor and possible tuck-in or partnership candidate.

10Akna Dx
TypeEmerging player
Description

Akna Dx is an emerging diagnostics company focused on maternal and women's health, including pregnancy complication risk. It is a smaller, more recent entrant in the same category Mirvie is building, and is a relevant emerging peer to track.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mirvie

Prenatal Diagnostic Testingmirvie.com

Mirvie is a molecular diagnostics company that uses its proprietary cell-free RNA platform and machine learning to predict pregnancy complications such as preeclampsia and preterm birth months before symptoms, selling its Encompass test direct-to-consumer and through healthcare and employer-benefit pilots.

What Mirvie does

Mirvie is a molecular diagnostics company that develops non-invasive blood tests designed to predict pregnancy complications months before clinical symptoms appear. Its proprietary Mirvie RNA Platform analyzes tens of thousands of cell-free RNA messages originating from the mother, baby, and placenta, combined with machine learning, to identify pregnancies at risk for preeclampsia, preterm birth, severe fetal growth restriction, and other complications. The company was founded in 2018 in South San Francisco, California, where it operates a CLIA-certified laboratory performing high-complexity clinical testing under a Breakthrough Device designation from the FDA granted in May 2022.

The company's first commercial product, the Encompass Preeclampsia Test, launched in May 2025 and is positioned as a direct-to-consumer kit taken between 18 and 22 weeks of gestation. Customers order through mirvie.com or encompassstest.com, receive a mailed kit, schedule an at-home blood draw through Getlabs mobile phlebotomists, and view results through the 1health.io platform. Encompass is bundled with a personalized preventive action plan and a responsive virtual assistant for ongoing support. Mirvie is also piloting the test with healthcare provider networks (Advantia Health) and employer benefits platforms (WIN / WINMaternity) to embed predictive screening into clinical and benefits workflows beyond DTC.

Mirvie has raised approximately $90 million in equity financing across seed and Series B rounds (notably a $60 million Series B led by Decheng Capital in May 2022), supplemented by a $15 million debt facility from Comerica Bank, a $4.6 million Bill & Melinda Gates Foundation grant for Sub-Saharan Africa research, and an additional 2025 financing reported by third-party data. Revenue is generated primarily through one-time per-test fees to consumers; the company does not publicly disclose pricing and has stated it makes no representation regarding insurance reimbursement.

Mirvie firmographics

Firmographics
Name
Mirvie
Legal name
Mirvie, Inc.
Website
https://mirvie.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Mirvie is a molecular diagnostics company that uses its proprietary cell-free RNA platform and machine learning to predict pregnancy complications such as preeclampsia and preterm birth months before symptoms, selling its Encompass test direct-to-consumer and through healthcare and employer-benefit pilots.
Ownership category
akta.pro rank

Mirvie industry classification

Industry
Product category
Prenatal Diagnostic Testing
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLALAHAK
Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)

Keywords

  • Prenatal diagnostic testing
  • Maternal-fetal health
  • Cell-free RNA analysis
  • Preeclampsia prediction
  • Non-invasive pregnancy testing

Where Mirvie is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mirvie business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Direct-to-Consumer Diagnostic Test Sales: Mirvie sells Encompass test kits directly to pregnant consumers through its e-commerce storefronts (mirvie.com and encompassstest.com). Customers pay for the test upfront, with installment payment options available. Results are delivered through a third-party platform (1health.io).

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goEncompass Preeclampsia Test — at-home blood test with results and preventive action plan

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Mirvie product offering

Product offering

Core offering

Mirvie develops and sells the Encompass Preeclampsia Test, a non-invasive at-home blood test taken between 18-22 weeks of gestation that predicts personalized preeclampsia risk months before symptoms appear. The test is powered by the proprietary Mirvie RNA Platform, which analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. The company also pursues enterprise healthcare partnerships with health systems and benefits providers to embed the test in clinical workflows.

Product overview

Mirvie offers a platform-plus-modules product architecture anchored by the Mirvie RNA Platform. The core platform combines analysis of tens of thousands of RNA messages from the baby, placenta, and mother with machine learning to predict pregnancy complications before symptoms occur. The first commercial product built on this platform is Encompass, which combines a novel blood test for personalized preeclampsia risk prediction with two supporting modules: a Preventive Action Plan and a responsive Virtual Assistant. Together, these provide pregnant women and their care teams with risk assessment, actionable guidance, and ongoing support for the healthiest pregnancy possible.

Differentiator

Problem solved

Functional benefit

Brands

  • Encompass: First-of-its-kind personalized risk prediction test for preeclampsia using a simple blood test, combined with a preventive action plan and responsive virtual assistant for individualized support during pregnancy.

Products and services

  • Encompass Preeclampsia Test A first-of-its-kind at-home blood test that predicts personalized preeclampsia risk months before symptoms appear, taken between 18-22 weeks of gestation. Combined with a preventive action plan and a responsive virtual assistant for individualized support throughout pregnancy. Powered by the proprietary Mirvie RNA Platform, it analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. Demonstrated 75% detection rate for preeclampsia overall and 91% identification of preterm preeclampsia in women aged 35+. For pregnant women seeking proactive, personalized pregnancy care and clinicians seeking biology-driven risk stratification.

Quantifiable outcome

  • Mirvie RNA platform identifies 75% of women who go on to develop preeclampsia, months before symptoms appear. Only 20% of pregnancy complications can be predicted using current generalized risk assessments.
  • +4 more outcomes

Companies that use Mirvie

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Mirvie technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature6 records

Mirvie partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • WIN (WINMaternity)coreStrategic or Co-development Partner · 31 July 2025WIN (WINMaternity) partnered with Mirvie to expand its maternal health program, integrating Mirvie's Encompass test for early preeclampsia prediction and prevention. The expanded program includes 24/7 Nurse Advocacy, virtual specialists, biological data-driven screening, and engagement rewards.
  • Advantia HealthcoreStrategic or Co-development Partner · 22 April 2025Mirvie and Advantia Health launched a first-of-its-kind pilot program in the U.S. using the Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia in asymptomatic pregnant women, enabling clinicians to initiate preventive care.
  • Centers for Medicare and Medicaid Services (CMS)coreTechnology or Integration · 26 September 2023Mirvie's South San Francisco-based laboratory received CLIA (Clinical Laboratory Improvement Amendments) certification from CMS to perform high-complexity clinical testing, enabling the company to offer its diagnostic tests clinically.
  • Getlabs, Inc.coreTechnology or Integration · 26 September 2023Getlabs provides mobile phlebotomist services for at-home blood draws for Mirvie's Encompass test. Customers schedule a blood draw through Getlabs, whose phlebotomist visits at the scheduled time and location. Use of Getlabs is subject to Getlabs Terms of Service.
  • 1health.io, Inc.coreTechnology or Integration · 26 September 20231health.io delivers Mirvie test results to users through its platform. Users create a 1health account to view their Encompass results. 1health also facilitates the account registration process including a health questionnaire. Use of 1health platform is subject to 1health Terms of Use.
  • Stanford University / Stephen Quake LabcoreTechnology or Integration · 27 April 2021Mirvie's proprietary RNA technology was invented at Stanford University through Stephen Quake's groundbreaking work on pregnancy-related cell-free RNA. Quake co-founded Mirvie and serves as Scientific Advisory Board Chair. The technology originated from Stanford research.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Mirvie competitors and assessment

Company assessment

Emerging players

  • Celula: Celula is an emerging diagnostics company developing cfRNA-based tests for pregnancy complications including preterm birth. It overlaps directly with Mirvie's RNA platform approach and represents a potential emerging competitor or future peer.
  • Progenity: Progenity is an emerging/specialized player in reproductive and maternal health diagnostics with products in prenatal testing and maternal health. It targets a similar OB-GYN channel with a narrower portfolio, making it a relevant emerging competitor and possible tuck-in or partnership candidate.
  • Akna Dx: Akna Dx is an emerging diagnostics company focused on maternal and women's health, including pregnancy complication risk. It is a smaller, more recent entrant in the same category Mirvie is building, and is a relevant emerging peer to track.

Broad incumbents

  • Natera: Natera is a major reproductive health diagnostics incumbent with the Panorama NIPT, Empower carrier screen, and Vistara single-gene NIPT, plus enterprise sales infrastructure into OB-GYN offices. It is the most established competitor in the channel Mirvie is pursuing and a natural bundler for cfRNA-based predictive tests.
  • Sema4 (now GeneDx): Sema4's reproductive health offering, now part of GeneDx, includes maternal screening and genetic testing. As a broader women's health and rare disease incumbent, it competes for the same hospital and health system relationships Mirvie is targeting with its enterprise pilots.
  • Laboratory Corporation of America (LabCorp): LabCorp is a broad diagnostics incumbent offering the MaterniT21 NIPT and a broad prenatal screening menu. It competes with Mirvie on OB-GYN access, payer contracts, and lab throughput, and is positioned to add cfRNA-based predictive tests to its existing menu.
  • Myriad Genetics: Myriad's Women's Health segment (Foresight, Prequel, SneakPeek) makes it a broad incumbent in carrier screening and NIPT. It has deep payer contracts and OB-GYN relationships that Mirvie must compete with for provider adoption of new predictive tests.
  • Invitae: Invitae (now part of Labcorp) offers reproductive health genetic testing including carrier screening and NIPT. As a broad incumbent, it competes with Mirvie for the same clinical relationships and payer contracts across prenatal and women's health.

Direct peers

  • Sera Prognostics: Sera Prognostics is a direct peer in pregnancy complication diagnostics, with the PreTRM test for spontaneous preterm birth risk prediction. They target the same OB-GYN and maternal-fetal medicine customer base with blood-based biomarker testing, competing head-to-head with Mirvie's preterm birth prediction offering.
  • BillionToOne: BillionToOne is a high-growth prenatal diagnostics peer offering UNITY Fetal Antigen and other NIPT products that screen for pregnancy complications. It serves the same pregnant-consumer and OB-GYN segments, and is a credible DTC and enterprise competitor in advanced prenatal screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mirvie social profiles

Digital presence

Mirvie compliance and trust

Trust signal

Compliance1 record

Mirvie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mirvie leadership team

Management profile

Number of profiles

Profiles13 records

Mirvie funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mirvie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirvie

What does Mirvie do?

Mirvie develops and sells the Encompass Preeclampsia Test, a non-invasive at-home blood test taken between 18-22 weeks of gestation that predicts personalized preeclampsia risk months before symptoms appear. The test is powered by the proprietary Mirvie RNA Platform, which analyzes tens of thousands of cell-free RNA messages from the baby, placenta, and mother using machine learning. The company also pursues enterprise healthcare partnerships with health systems and benefits providers to embed the test in clinical workflows.

Is Mirvie a public or private company?

Mirvie is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mirvie founded?

Mirvie was founded in 2018. It employs 11 to 50 people.

Where is Mirvie based?

Mirvie is headquartered in South San Francisco, United States, in the North America region.

How does Mirvie make money?

One revenue line is on record: direct-to-Consumer Diagnostic Test Sales.

Who are Mirvie's main competitors?

Emerging players on record are Celula, Progenity and Akna Dx. Broad incumbents are Natera, Sema4 (now GeneDx), Laboratory Corporation of America (LabCorp), Myriad Genetics and Invitae. Direct peers are Sera Prognostics and BillionToOne.

Does Mirvie have an API?

No public API is recorded for Mirvie.

What industry is Mirvie in?

Mirvie's product category is Prenatal Diagnostic Testing. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSlone Partners Places David Stern as Chief Executive Officer of MirvieSlone Partners placed David Stern as CEO of Mirvie, a pregnancy health company, on Nov. 10, 2026. Stern previously led Kindbody and Boston IVF, and Mirvie's co-founder Maneesh Jain will transition to Executive Vice Chair. Stern aims to scale Mirvie's RNA platform for early risk detection of pregnancy complications.PR NewswireWIN Expands Maternal Health Program and Introduces Early Preeclampsia Prediction and Prevention Program Powered by Mirvie's EncompassWIN, the nation's leading family-building benefits provider, announced the expansion of its WINMaternity program through a partnership with Mirvie to offer the Encompass blood test for personalized preeclampsia risk assessment, marking the first benefits provider to integrate this predictive screening tool. The expanded program includes 24/7 Nurse Advocacy, virtual maternity specialists, doula and lactation support, and a preventive action plan with digital monitoring tools, addressing a condition that affects 1 in 12 U.S. pregnancies and contributes up to $10 billion annually in healthcare costs. Major employers such as Hertz are already utilizing the program, which aims to reduce preventable maternal deaths through earlier, data-driven interventions.SheKnowsThis New Test Can Detect Preeclampsia Months Before Symptoms OccurMirvie has launched the Encompass blood test in the United States, a diagnostic tool designed to predict the risk of preeclampsia months before symptoms appear by analyzing cell-free RNA measurements. The test utilizes data from nearly 11,000 pregnancies and is marketed directly to consumers aged 35 and older via an e-commerce platform with telehealth support. This innovation aims to enable earlier interventions for high-risk pregnancies, addressing a condition that disproportionately affects Black women and carries significant maternal and fetal health risks.ForbesHow Two Fathers Turned Personal Crisis Into Preeclampsia InnovationMirvie, co-founded by Maneesh Jain and Stephen Quake, uses an RNA-based blood test to predict preeclampsia. The test identified 91% of women who developed preterm preeclampsia, with low-risk patients having a 99.7% chance of not developing the condition. The company has raised over $75 million in venture capital.FinancialContent Business PageInternational Business TimesMirvie launched Encompass, a blood test predicting preeclampsia risk months before symptoms appear. The test, based on cell-free RNA analysis of nearly 11,000 pregnancies, predicted 9 of 10 cases of preterm preeclampsia as high risk, with low-risk results having a 99.7% probability of not developing the condition. It is available to pregnant women aged 35 and older at delivery.Business Wire BlogIntroducing Encompass™: A Breakthrough Solution from Mirvie to Advance Care for Pregnancy ComplicationsMirvie launched Encompass, a preeclampsia risk test using cell-free RNA analysis, available to pregnant women aged 35+ in the U.S. The test predicted 9 of 10 pregnancies that later developed preterm preeclampsia as high risk, with low-risk results having a 99.7% probability of not developing the condition.trib.alHow Mirvie is building an RNA platform to predict pregnancy complications soonerMirvie is developing an RNA platform to predict pregnancy complications like preeclampsia and preterm labor months in advance. The startup raised $90 million and its platform has received FDA breakthrough device designation. It aims to bring RNA testing to OB/GYN offices.HealthtransformerStartUp Health Insights: Pregnancy and Children’s Health Startups Raise Rounds | Week of May 24, 2022Multiple startups focused on pregnancy, children's health, and related fields raised over $250 million through various funding rounds in late May 2022. Notable deals included Mirvie's $60 million Series B and other investments in healthcare technology startups across the US, Singapore, Israel, and Germany.HomepageBiotech Company Mirvie Raises $60M for Its RNA Platform Focused on Early Prediction of Pregnancy ComplicationsMirvie, a biotech developing an RNA platform that analyzes RNA messages from baby, placenta and mother, raised $60 million led by Decheng Capital, with backing from BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, Mayfield and Comerica Bank. The company has raised $90 million total. Its platform predicts preeclampsia and preterm birth months in advance, with FDA Breakthrough Device designation.MobiHealthNewsMirvie raises $60M to develop early preeclampsia detection and more digital health fundingsMirvie raised $60 million in Series B funding led by Decheng Capital to develop a blood test for early preeclampsia detection. The article also reports that Greater Good Health secured $10 million to support nurse practitioners and ThoroughCare obtained $3 million for its care coordination software.